<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80562">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01834547</url>
  </required_header>
  <id_info>
    <org_study_id>1234</org_study_id>
    <nct_id>NCT01834547</nct_id>
  </id_info>
  <brief_title>Cognitive Hyper-performance - Effects of Stimulating Substances in Chess-players</brief_title>
  <acronym>CHESS</acronym>
  <official_title>Phase I Study About Effects of Caffeine, Methylphenidate, Modafinil and Placebo on Cognitive Performance of Chess Players.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>K. Lieb</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effects of caffeine, methylphenidate, modafinil and placebo on cognitive performance of
      chess players in chess games and neuropsychiatric standardized tests. We hypothesize that
      substances will change cognitive performance in chess players leading to changed results in
      chess games and neuropsychiatric tests.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>Chess games (win/ lose/ tie)</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>time period for decision of chess games</measure>
    <time_frame>results of ches games</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive performance measured with standardized neuropsychiatric tests (Tower of Hanoi, Trail-Making test, Stroop-Test, Psycho-Motor-Vigilance test, Wisconsin-Card-Sorting-Test, Balloon Analog Risk Task)</measure>
    <time_frame>outcome of tests</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measuring of risk taking behaviour, motivation, mood using standardized questionnaires</measure>
    <time_frame>outcome of tests</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>type of adverse events</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Cognitively Healthy Subjects Influenced by Psychoactive Drugs</condition>
  <arm_group>
    <arm_group_label>Methylphenidate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methylphenidate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>modafinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>modafinil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>caffeine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>caffeine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drugs use: methylphenidate</intervention_name>
    <description>40 mg tablets</description>
    <arm_group_label>Methylphenidate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug use: modafinil</intervention_name>
    <description>40 mg tablets</description>
    <arm_group_label>modafinil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>caffeine</intervention_name>
    <description>400 mg</description>
    <arm_group_label>caffeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male

          -  18-60 years old

          -  existence of ELO-number

        Exclusion Criteria:

          -  physical diseases (e.g. diabetes mellitus, etc.) with necessity of using prescription
             drugs

          -  psychiatric diseases (e.g. psychosis, bipolar disorders, etc.) with necessity of
             using prescription drugs

          -  addiction of psychoactive substances

          -  smoker or quitter (&lt; 5 years)

          -  use of more than 5 cups of coffee per day

          -  irregular day-night-rhythm (e.g. shift workers)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Psychiatry and Psychotherapy</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 17, 2013</lastchanged_date>
  <firstreceived_date>May 25, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>K. Lieb</investigator_full_name>
    <investigator_title>Prof. Dr. med. K. Lieb</investigator_title>
  </responsible_party>
  <keyword>chess, cognition</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Methylphenidate</mesh_term>
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
